Dublin, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The "Licensing Deals in Biotechnology 2020-2026" has been added to ResearchAndMarkets.com's offering.
Fully revised and updated, the report provides detailed information on 2,500+ biotechnology licensing deals announced between 2020 and 2026, offering a broad view of licensing activity across emerging technologies and therapeutic areas. Each transaction includes financial information where available and links to online deal records and contract documents filed with regulators when publicly disclosed.
The report provides a comprehensive analysis of licensing agreements across the global biotechnology sector. Designed for business development, licensing, legal, and strategy professionals, the report delivers detailed insight into how companies structure licensing partnerships, negotiate financial terms, and allocate development and commercialization rights.
By combining detailed deal data, financial benchmarking, and access to real contract agreements, the report provides valuable intelligence for evaluating partners, structuring licensing agreements, and negotiating stronger deal terms.
Key Benefits
- Save Significant Research Time: Access a comprehensive database of biotechnology licensing deals instead of searching multiple databases, press releases, and regulatory filings.
- Benchmark Licensing Deal Structures: Understand how biotechnology companies structure licensing partnerships, including development responsibilities, territorial rights, and commercialization arrangements.
- Analyze Financial Terms with Confidence: Review disclosed financial terms including upfront payments, milestone payments, and royalty structures, enabling accurate benchmarking of licensing deal value.
- Access Real Contract Documents: Where available, review actual licensing agreements filed with the SEC, providing deeper insight into the contractual provisions behind real-world deals.
- Identify Active Licensing Dealmakers: Discover which biotechnology companies are most active in licensing partnerships and analyze their dealmaking strategies.
- Track Industry Trends: Analyze licensing activity since 2020 across companies, therapeutic areas, and technologies to understand how partnering strategies are evolving in the biotech sector.
What's Included in the Report
- Analysis of biotechnology licensing dealmaking trends since 2020
- Overview of licensing deal structures and financial models
- Review of leading licensing deals by disclosed value
- Profiles of the top 25 most active licensing dealmakers
- Detailed analysis of deals organized by company, therapeutic area, technology type, and industry segment
- A comprehensive deal directory covering licensing deals announced since 2020
- Links to online deal records and contract documents where available
Due Diligence Insights from Real Agreements
By reviewing actual licensing contracts, the report enables users to evaluate key partnership provisions such as:
- Rights granted or optioned under the license
- Upfront payments, milestones, and royalty structures
- Intellectual property ownership and licensing scope
- Development, manufacturing, and commercialization responsibilities
- Exclusivity provisions and territorial rights
- Contract duration and termination clauses
Analyzing these agreements provides valuable insight into how licensing partnerships are negotiated and structured across the biotechnology industry.
Why This Report Matters
Licensing partnerships are central to innovation in biotechnology, allowing companies to access new technologies, share development risk, and accelerate product development.
By combining comprehensive deal data, financial benchmarking, and access to real contract documents, this report provides the intelligence needed to structure stronger licensing partnerships and negotiate more effectively.
Companies Featured
- AbCellera Biologics
- Adaptive Biotechnologies
- Adicet Bio
- Akeso Biopharma
- Alnylam Pharmaceuticals
- Amgen
- Apellis Pharmaceuticals
- Arcturus Therapeutics
- Beam Therapeutics
- BioMarin Pharmaceutical
- BioNTech
- BlueRock Therapeutics
- BridgeBio Pharma
- Caribou Biosciences
- Celltrion
- CRISPR Therapeutics
- CureVac
- Daiichi Sankyo
- Denali Therapeutics
- Editas Medicine
- Eli Lilly
- Evotec
- Fate Therapeutics
- Genentech
- Gilead Sciences
- Ginkgo BioWorks
- Halozyme Therapeutics
- Illumina
- Immunocore
- Intellia Therapeutics
- Ionis Pharmaceuticals
- Legend Biotech
- Lonza
- Mammoth Biosciences
- Moderna
- Novartis
- Novo Nordisk
- Oxford BioMedica
- Pacific Biosciences
- Pfizer
- Regeneron Pharmaceuticals
- Roche
- Sana Biotechnology
- Sangamo Therapeutics
- Sanofi
- Sarepta Therapeutics
- Takeda Pharmaceutical
- Vertex Pharmaceuticals
- Voyager Therapeutics
- WuXi Biologics
For more information about this report visit https://www.researchandmarkets.com/r/m9xuf3
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
